Formulation development and optimization of Lamivudine 300 mg and Tenofovir Disoproxil Fumarate (TDF) 300 mg FDC tablets by D-optimal mixture design

Formulation development and optimization of Lamivudine 300 mg and Tenofovir Disoproxil Fumarate (TDF) 300 mg FDC tablets by D-optimal mixture design

The usage of fixed dose combination (FDC) tablets of Lamivudine and Tenofovir Disoproxil Fumarate (TDF) is increasing due to increased incidences of HIV/Hepatitis B and HIV/TB co-infections. This is likely to increase the financial crisis due to limited resources for funding procurement of ready-mad...

Full description

Bibliographic Details
Main Authors: Tibalinda, Prosper, Sempombe, Joseph, Shedafa, Raphael, Masota, Nelson, Pius, Dickson, Temu, Mary, Kaale, Eliangiringa
Format: Online
Language:English
Published: Elsevier 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137174/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137174/

Similar Items